Role, Responsibilities, and Strategic Considerations for Medical Device Manufacturers
Notified Bodies (NBs) are independent conformity assessment organizations designated by EU Member States and overseen by the European Commission. Under the EU MDR and EU IVDR, Notified Bodies serve as the primary gatekeepers for market access for most Class IIa, IIb, III, and in vitro diagnostic devices.
For manufacturers, engaging a Notified Body is not a one-time regulatory step. It is a long-term regulatory relationship that directly impacts product approval, timelines, and commercial success.
What is a Notified Body?
A Notified Body is a third-party organization authorized to assess whether a medical device meets EU regulatory requirements. Upon successful assessment, the Notified Body issues the certificates required for CE marking.
Without Notified Body involvement, most moderate- and high-risk devices cannot be legally marketed in the European Union.
Core Responsibilities of Notified Bodies
Quality Management System (QMS) Assessment
Notified Bodies evaluate the manufacturer’s quality system, typically aligned with ISO 13485. This includes key quality system areas of management responsibility and oversight, design and development controls, supplier and purchasing controls, production and process controls, and CAPA and complaint handling systems.
Technical Documentation Review
Notified Bodies conduct in-depth reviews of technical files or design dossiers, confirming details about the device description and intended use, risk management (ISO 14971 alignment), design verification and validation, biocompatibility, software validation, and usability, labeling, and Instructions for Use (IFU).
Clinical / Performance Evaluation
Under MDR and IVDR, clinical evidence requirements are significantly strengthened. Notified Bodies assess manufacturers’ Clinical Evaluation Reports (CERs), Performance Evaluation Reports (PERs), clinical data adequacy and relevance, and Post-Market Clinical Follow-up (PMCF) plans.
Device Classification Verification
Notified Bodies confirm the manufacturer’s classification rationale based on MDR/IVDR rules. Device misclassification is a common cause of delays.
Certification and CE Marking
Upon successful assessment, the Notified Body will issue a QMS Certificate and a CE Certificate (product or product family). The certificates enable the manufacturer to affix the CE mark and place the device on the EU market.
Lifecycle Oversight: Ongoing Regulatory Control
Notified Body involvement continues throughout the product lifecycle.
Surveillance Activities
Notified Body surveillance activities include annual surveillance audits, recertification audits (every 3–5 years), and risk-based unannounced audits.
Post-Market Oversight
A Notified Body’s post-market oversight of the manufacturer includes a review of Periodic Safety Update Reports (PSURs), an evaluation of vigilance data and trend reporting, and oversight of post-market surveillance systems.
Change Management
Manufacturers must notify the Notified Body of significant changes, including design modifications, intended use changes, and manufacturing or supplier changes. Failure to obtain NB approval for any of the changes can invalidate certification.
Increased Scrutiny Under MDR and IVDR
Compared to legacy EU directives, Notified Bodies now operate under stricter regulatory expectations of higher clinical evidence thresholds, an increased emphasis on risk-benefit justification, greater transparency and traceability (UDI, EUDAMED), and additional scrutiny procedures for high-risk devices. This results in more detailed reviews, longer timelines, and higher expectations for manufacturers.
Notified Body Designation and Oversight
Notified Bodies themselves are highly regulated and must meet stringent criteria to maintain designation. They are designated by EU Member States, jointly assessed by national authorities and the European Commission, and are subject to periodic reassessment and performance monitoring.
This increased scrutiny of Notified Bodies has led to fewer Notified Bodies and limited capacity across the EU.
Commercial Realities: What Manufacturers Need to Know
Limited Capacity and Long Timelines
As mentioned, the MDR/IVDR transition has led to reduced availability of Notified Bodies. As a result, review timelines often range from 6 to 18+ months.
Cost Considerations
Notified Body engagement includes initial certification fees, annual audit fees, technical documentation review costs, and change assessment fees.
Early Engagement is Critical
Successful manufacturers will engage NBs early in development, conduct pre-submission readiness assessments, and ensure that QMS and technical documentation are fully mature.
EU vs. U.S. FDA: Key Differences
| European Union | United States |
| Notified Bodies perform conformity assessment | FDA performs centralized review |
| CE marking required for market access | 510(k), De Novo, or PMA pathways |
| QMS certification required | QMS compliance (no certification) |
| Continuous NB oversight | FDA inspections and postmarket controls |
In the EU, unlike the centralized FDA model regulatory authority is partially delegated to Notified Bodies.
Implications for Manufacturers
Notified Body interaction is often the most critical factor in EU regulatory success.
Common risks include delayed market entry, certification refusal, increased regulatory costs, and commercial disruption. And success depends on having high-quality technical documentation, robust clinical evidence, and mature, audit-ready quality systems.
